We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.43% | 1.15 | 1.02 | 1.255 | 1.27 | 1.27 | 1.27 | 733,994 | 16:35:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -2.92M | -0.0070 | -1.81 | 4.81M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/8/2024 10:07 | So keep your money in your pocket then Nobby 😎 | socionomics | |
14/8/2024 09:57 | Well the chart shows the price is most definitely in a long term downtrend and short term is in the middle of a trading range. That does not indicate a rise is imminent to me…. | nobbygnome | |
14/8/2024 09:30 | Not everyone who picks up a paintbrush is a Picasso. | socionomics | |
14/8/2024 09:05 | I think the gerbil is likely to do better as it isn't subject to your biases. | supernumerary | |
14/8/2024 07:11 | All of which just goes to show how pointless it is to rely on charts. Two posters here manage to draw very different conclusions from the exact same graph. A graph, at that, which is backwards-looking. You might as well ask your pet gerbil to forecast. | lord loads of lolly | |
14/8/2024 05:03 | Thanks for the reply….but I absolutely don’t see that. From my view the price is in the middle of a trading range and could go either way…. | nobbygnome | |
13/8/2024 20:56 | Nobby, so far as I can ascertain on charting, the share price is sitting right on the resistance / support level. If it rises the top of the trading range will be 2.5 p. In candle chart, it is a white candle (rising) so I am inclined to say that it will rise to 2.5 p in the next cycle. | kingston78 | |
13/8/2024 19:35 | The current chart looks poor to me; I certainly wouldn’t buy after glancing at it! Please explain why you think it’s positive…. | nobbygnome | |
13/8/2024 19:21 | That's because they only tell you what's already happened. | supernumerary | |
13/8/2024 17:46 | Wait and see fellas. The charts never lie. | socionomics | |
13/8/2024 14:05 | Thanks Nobby - much appreciated.No logical reason why there should be any upward movement of the share price in the near future then.Time to go back to sleep | husbod | |
12/8/2024 15:40 | Well they haven’t even submitted the IND for the CIDP indication so that’s ages away from starting. As for SLE, well that’s down to Avion. It’s always been a concern of mine that Avion have no experience in SLE. It’s a very complicated indication with a high placebo response, the possibility of other drugs such as steroids confounding the results and a heterogeneous range of symptoms. So clearly Avion are struggling to get it off the ground which is why it would appear that the earliest results could be out is 2027. Of course we haven’t seen the protocol yet so don’t know the length of dosing, which makes it a little difficult to predict. In addition there is dose ranging incorporated in the design which adds complexity. So all in all it’s about as clear as mud at the moment…. | nobbygnome | |
12/8/2024 13:17 | Hi NobbyAlthough I remain a holder it's not a share I have really followed over the last couple of years so any chance you could give me a brief summary of where we are on the long delayed phase 3 approval application.Btw Socio et moi are doing quite nicely on another pharma tiddler STX, although granted it does have an FDA approved product. | husbod | |
12/8/2024 11:34 | Oh and if I do buy I want socionomics to go into full ramp mode….although his last attempt was a pitiful failure! Can’t complain about Incanthera though..well done Tim; you are a hero! | nobbygnome | |
12/8/2024 11:30 | LOL at least you admit I called this exactly right! I’m most definitely not a holder although it may be worth a punt if they ever get round to actually starting the phase III. Results in 2027 anyone…. | nobbygnome | |
12/8/2024 11:30 | Double post | nobbygnome | |
02/8/2024 08:10 | It looks like the ramp failed…. | nobbygnome | |
01/8/2024 17:29 | Short this dog. | ken chung | |
01/8/2024 08:42 | P3 hasn’t even started yet so difficult to know when they are due!😆 | nobbygnome | |
01/8/2024 08:25 | Nobby will know Mr P. He's the resident expert on IMM. | socionomics | |
31/7/2024 21:55 | P3 results due? | mr pierrepoint | |
31/7/2024 12:58 | 6p minimum target. (keep 14p in the back of your mind too.) Please note: This is just ramping. I am never right! I just got lucky on CPX, CPI, GDR, MTRO, BT, STX, SBTX, and others, to name a few from 2024. | socionomics | |
31/7/2024 12:54 | Yep, it's all just ramping Nobby. Nothing to see here. | socionomics |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions